We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Blog / Lexology Insights: Pharmaceuticals and biotechnology


14 March 2018

In this post, we will explore which topics and article have been popular in the pharmaceutical and biotechnology sector so far in 2018.

Most popular work areas:

Pharmaceutical and biotechnology reads on Lexology have focused on a mixture of industry-specific and general commercial work areas.  Aside from the perennially popular litigation work area, healthcare and life sciences and patents were the best-read work areas, reflecting the importance of R&D and IP protection and litigation for the sector.  Beyond that, IT and data protection proved as popular as employment and labour - two work areas relevant to all businesses, particularly with the upcoming implementation of the European Union's GDPR.

Most popular tags:

With its far reaching consequences and fast-approaching deadline, 'GDPR' has been the most popular tag across all of Lexology so far in 2018, and that is no different in the pharmaceutical and biotechnology sector. IP-related tags such as 'patent infringement', 'US PTO', 'EPO' and 'Unified Patent Court' have also been popular.

Most popular firms:

  1. Baker McKenzie
  2. Hogan Lovells
  3. Taylor Wessing
  4. Allen & Overy LLP
  5. IAM
  6. Reed Smith LLP
  7. Squire Patton Boggs
  8. Herbert Smith Freehills LLP
  9. McDermott Will & Emery
  10. Bristows LLP

 Most popular articles:

  1. Clinical trials in France, Reed Smith LLP
  2. CJEU ruling in Hoffmann-La Roche published on 23 January, Trevisan & Cuonzo Avvocati
  3. When is an exclusive licence not an exclusive licence? - Common sense and the present tense prevail! Brodies LLP
  4. The duration of your SPCs may potentially be extended, Novagraaf
  5. Life Sciences: Compliance and enforcement in the European Union, Hogan Lovells
  6. French Competition Authority Fines a Pharmaceutical Laboratory EUR 25 Million for Anti-Generic Practices, McDermott Will & Emery
  7. CRISPR European patent cancellation highlights procedural IP pitfalls, IAM
  8. ECJ finds that arrangement between Hoffmann-La Roche and Novartis may restrict competition “by object”, Slaughter and May
  9. FDA Proposes to Delay Off-Label “Intended Use” Rule, Reed Smith LLP
  10. Supplementary protection certificates 2: how must a product be identified in a patent for the purpose of SPC protection? Taylor Wessing
  11. EU General Court rules on transparency of clinical trial data, Allen & Overy LLP
  12. SPCs: where are we and where are we going? Taylor Wessing
  13. Pharmaceutical Sales Rep Gets 65-Month Sentence in Fraud Scheme, FisherBroyles LLP
  14. Patents: supplementary protection certificates, Bird & Bird
  15. Patent Prosecutors Beware: Earlier Publication Anticipates Broad Claims of Continuing Application, Jones Day
  16. Trends and practice tips in therapeutic antibody patenting, Banner & Witcoff Ltd
  17. Clarity on timing of German court challenge, Potter Clarkson LLP
  18. Combination of active ingredients - scope of protection - Gilead, Dechert LLP
  19. Judge Forrest: Vegetarian Who Unwittingly Bought Fries Cooked in Beef Tallow Not “Injured” for Purposes of NY’s Consumer Fraud Law, Steptoe & Johnson LLP
  20. The Unified Patent Court: Protective letters, Accura Advokatpartnerselskab